{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-182057","form_type":"8-K","ticker":null,"cik":"0001780097","company_name":"Baudax Bio, Inc.","filed_at":"2023-07-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.199281+00:00","generated_at":"2026-06-13T12:46:01.502944+00:00","sec_items":["1.01","5.03","2.01","3.02","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Baudax Bio acquires TeraImmune in stock-for-stock merger; issues preferred shares convertible to common","bullets":["Baudax Bio issued 1,212,185 common shares and 27,089.719 Series X convertible preferred shares (each convertible into 1,000 common) to TeraImmune stockholders.","Post-merger Baudax Bio had 7,276,149 shares of common stock outstanding; certain shares subject to 180-day lock-up.","Special shareholder meeting required to approve conversion of Series X Preferred Stock; failure may trigger cash settlement at fair value.","Baudax Bio entered a 30-day forbearance agreement with lenders under its credit facility related to the merger.","Yong Chan Kim, PhD (former TeraImmune CEO) appointed to Baudax Bio's board effective July 3, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-182057","json":"https://secwatch.observer/filing/0001193125-23-182057.json","markdown":"https://secwatch.observer/filing/0001193125-23-182057.md","text":"https://secwatch.observer/filing/0001193125-23-182057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523182057/0001193125-23-182057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523182057/d367312d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T12:46:01.502944+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"694de2c9ec","claim":"Yong Chan Kim was appointed as member of the Board at Baudax Bio, Inc..","evidence_excerpt":"On July 3, 2023, the Board appointed Yong Chan Kim, Ph.D., as a member of the Board, effective as of July 3, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523182057/0001193125-23-182057-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"member of the Board"}],"fact_type":"executive_change"},{"claim_id":"b2845080d3aa000d19aa989ceb9acae071b487bd","claim":"Baudax Bio, Inc.: Filed Certificate of Designation for Series X Non-Voting Convertible Preferred Stock (effective 2023-07-03).","evidence_excerpt":"On the Effective Date, Baudax Bio filed a Certificate of Designation of Preferences, Rights and Limitations of Series X Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523182057/0001193125-23-182057-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-07-03"}],"fact_type":"governance_change"},{"claim_id":"a93d0b86c47cce344bf5d63fe0a4f8c938caec76","claim":"Baudax Bio, Inc. completed an acquisition involving TeraImmune, Inc. (closed 2023-06-29).","evidence_excerpt":"On the Effective Date, Baudax Bio completed its business combination with TeraImmune.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523182057/0001193125-23-182057-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"TeraImmune, Inc."},{"label":"Closing","value":"2023-06-29"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}